logo
Share SHARE
FONT-SIZE Plus   Neg

CHMP Adopts Positive Opinion On ADASUVE - Quick Facts

Alexza Pharmaceuticals, Inc. (ALXA) and Grupo Ferrer Internacional, S.A., announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending that ADASUVE be granted European Union centralized marketing authorization.

The CHMP recommends ADASUVE be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.

The CHMP positive opinion will now be forwarded to the European Commission. The company expects a decision from the European Commission in the first quarter of 2013.

Alexza filed the ADASUVE Marketing Authorization Application with the European Medicines Agency in October 2011.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
German auto giant BMW Group (BMW.L, BAMXF.PK, BAMXY.PK) reported Tuesday higher net profit in its first quarter, while EBIT, a key earnings metric, declined on weak automotive revenues. Sales volumes, however, increased from last year. Further, the company confirmed its fiscal 2016 forecast, expecting slight increases. BMW shares were losing around 3 percent in the morning trading in Germany. Shares of UBS AG were losing around 5 percent in the morning trading after the Swiss financial services giant reported Tuesday sharply lower profit in its first quarter amid lower net fee and commission as well as trading income. Net interest income, however, improved from last year. Looking ahead, the company said that the ongoing underlying macroeconomic challenges and geopolitical risks ... Asia-focused lender HSBC Holdings Plc reported Tuesday a decline in the first-quarter profit, on weak revenues and net interest income. The results reflected weak performance in all segments and business regions, except Middle East and North Africa as well as CMB.
comments powered by Disqus
Follow RTT